Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels

Area of Science:

• Immunology
• Endocrinology
• Molecular Biology

Background:

• Previous studies showed vitamin D analogs inhibit TNFalpha production by macrophages.
• The mechanism of this inhibition, specifically involving NFkappaB, was not fully understood.

Purpose of the Study:

• To investigate if vitamin D analogs inhibit TNFalpha via the transcription factor NFkappaB.
• To elucidate the molecular mechanisms underlying vitamin D's anti-inflammatory effects.

Main Methods:

• Murine macrophage cells were treated with vitamin D analogs (1,25(OH)(2)D(3) or 1,24(OH)(2)D(2)) and stimulated with lipopolysaccharide.
• NFkappaB activity was measured using reporter gene assays and electrophoretic mobility shift assays (EMSA).
• Levels of NFkappaB-p65, IkappaBalpha, and phosphorylated IkappaBalpha were assessed at the mRNA and protein levels.

Main Results:

• Both vitamin D analogs significantly reduced TNFalpha secretion by 60%.
• Vitamin D treatment markedly decreased NFkappaB activity, evidenced by reduced nuclear NFkappaB-p65 and increased cytosolic levels.
• Vitamin D increased IkappaBalpha mRNA and protein levels by stabilizing mRNA and reducing phosphorylation.

Conclusions:

• Vitamin D up-regulates IkappaBalpha, leading to reduced NFkappaB nuclear translocation and activity.
• This mechanism explains vitamin D's inhibition of inflammatory mediators like TNFalpha.
• The less-calcaemic analog 1,24(OH)(2)D(2) shows promise as an anti-inflammatory therapeutic agent.